Credit: Qure.ai
Indian startup Qure.ai last week announced the company s separate partnerships to have its AI-powered software used for screening various diseases such as COVID-19 and tuberculosis.
It teamed up with Fujifilm Corporation to equip the brand s smart radiograph system with artificial intelligence, while it also partnered with AstraZeneca Malaysia to use its AI diagnostics software to support the early detection of lung cancer in Malaysia.
WHY IT MATTERS
Qure.ai brings qXR, its deep-learning AI technology software, to Fujifilm s portable X-ray FDR Xair system, enabling the device to analyse radiographs and detect abnormal findings within seconds. The integration of the AI software into the device was made possible through an image processing box called Expansion Unit EX-Mobile.
Mary Day, Chief Executive, St James’s Hospital, Dublin.
St James’s Hospital is Ireland’s largest acute academic teaching hospital, occupying a prominent position at the forefront of the Irish health sector.
In partnership with its academic partner, Trinity College Dublin, its overarching ambition is to create a dynamic healthcare campus, which will be a leading healthcare organisation, nationally and internationally, improving health outcomes through collaboration, education, research and innovation.
What is your day to day responsibilities?
As a Hospital Chief Executive, I have the responsibility to ensure all aspects of how the hospital performs are working efficiently. This involves a balance in managing the day-to-day operations while leading strategic development initiatives required for long-term success. Overall, I am responsible for management of the hospital ensuring appropriate planning, management and control of services within allocated resources.
HKSTP, AstraZeneca push Hong Kong as biomedical innovation hub
HKSTP, AstraZeneca push Hong Kong as biomedical innovation hub 16 February 2021 | News
Photo Credit: HKSTP
AstraZeneca and the Hong Kong Science and Technology Parks Corporation (HKSTP) have launched a co-incubation programme to support biomedical startups in their mission to develop integrated oncology solutions to accelerate innovation in oncology, foster local biomedical technologies and enhance Hong Kong’s status as a leading biomedical innovation hub.
In the last decade, malignant cancerous tumours have been the number one cause of death among all diseases in Hong Kong. Today’s cancer treatment solutions, physical check-ups, diagnosis, treatment, follow-up and rehabilitation, are all interrelated. Improvements in either aspect of the patient journey will create huge opportunities to drive better treatment outcomes.